B. Douglas Smith, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans Street, Room 246, CRB1, Baltimore, MD 21231-1000, USA. Disclosure: The authors have no relevant ...
Preliminary data supports BMF-500’s potential as a transformative therapy for patients with FLT3 mutated relapsed or refractory (R/R) acute leukemia BMF-500 showed a favorable safety and tolerability ...
Efficacy of CAR-T cell therapy versus allogeneic stem cell transplantation in relapsed/refractory B-acute lymphoblastic leukemia: A systematic review of 12 clinical trials. This is an ASCO Meeting ...
The case study, which showed prolonged disease control achieved with gilteritinib in a previously-treated patient with AML with an inv(2)(p23q13) translocation, indicates that gilteritinib can also be ...
TORONTO, June 16, 2025 /CNW/ - Daiichi Sankyo's (TSE: 4568) VANFLYTA (quizartinib) has been approved by Health Canada for use in combination with standard cytarabine and anthracycline induction and ...
Factors associated with occurrence of acute leukemias and myelodyplastic neoplasms as seen at the Kenyatta National Hospital, Nairobi, Kenya. Real-world adherence and tolerability of FLT3 inhibitors ...
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today highlighted data presented at the American Association ...
NUP98-NSD1 and NUP98-KDM5A fusions are linked to poor prognosis in AML, affecting OS and EFS significantly. NUP98-NSD1 is more common in pediatric AML, necessitating alternative detection methods like ...
A study of a real-world population underscores measurable residual disease thresholds indicative of the risk for relapse in NPM1-mutated AML, suggesting guidance in treatment decisions.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results